Mediwound Ltd (MDWD)

Currency in USD
12.100
0.000(0.00%)
Closed·
Advertisement
MDWD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.01012.470
52 wk Range
11.84019.700
Key Statistics
Prev. Close
12.1
Open
12.08
Day's Range
12.01-12.47
52 wk Range
11.84-19.7
Volume
155.32K
Average Volume (3m)
89.09K
1-Year Change
-34.9462%
Book Value / Share
2.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDWD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
30.667
Upside
+153.44%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Mediwound Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 30.667
(+153.44% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy25.00+106.61%-Maintain24/09/2026
Oppenheimer
Buy30.00+147.93%32.00Maintain14/08/2026
Oppenheimer
Buy32.00+164.46%33.00Maintain27/05/2026
H.C. Wainwright
Buy36.00+197.52%31.00Maintain21/11/2025

Mediwound Ltd Earnings Call Summary for Q2/2026

  • Q2 revenue of $3.1M beat forecast by 7.3% but fell 45.6% YoY due to timing of BARDA-funded development revenue; shares rose 1.87% to $14.17.
  • Company reaffirmed FY2026 revenue guidance of $24M-$26M, weighted to H2, driven by Vericel MSA, government programs, and NexoBrid commercial sales.
  • EscharEx phase III trial at 90% site activation, targeting enrollment completion by Q1 2027; updated peak U.S. sales potential raised to $1.05B from $800M.
  • Operating loss widened to $9.5M from $5.7M YoY as R&D spending jumped to $5.9M; cash declined to $36M from $54M at year-end 2025 amid burn rate.
  • NexoBrid posted strongest quarter since Vericel launch; EMA-requested manufacturing modifications expected Q4 2026, with expanded facility supply in H2 2027.
Last Updated: 13/08/2026, 15:00
Read Full Transcript

Earnings

Latest Release
13/08/2026
EPS / Forecast
-0.77 / -0.74
Revenue / Forecast
3.09M / 2.89M
EPS Revisions
Last 90 days

Compare MDWD to Peers and Sector

Metrics to compare
MDWD
Peers
Sector
Relationship
P/E Ratio
−7.7x−0.9x−0.3x
PEG Ratio
−0.53−0.030.00
Price/Book
4.4x0.9x2.6x
Price / LTM Sales
13.2x1.9x2.9x
Upside (Analyst Target)
153.4%101.8%62.9%
Fair Value Upside
Unlock20.1%8.1%Unlock

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Employees
121

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.01M15.54%25.48M
Other Institutional Investors
9.54M73.91%121.19M
Public Companies & Retail Investors
1.36M10.54%17.29M
Total
12.91M100.00%163.96M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
HOLD Fund Management Ltd10.44%1,348,32317,124
Clal Life Sciences L.P.9.08%1,172,71014,893

People Also Watch

6.37
LFCR
0.00%
1.2000
DCX
-5.51%
0.48
QNME
+2.11%
1.540
OKYO
+12.41%

FAQ

What Is the Mediwound (NASDAQ: MDWD) Share Price Today?

The Mediwound stock price today is 12.100 USD.

What Stock Exchange Does Mediwound (MDWD) Trade On?

Mediwound is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Mediwound?

The stock symbol (also called a 'ticker') for Mediwound is "MDWD."

What Is the Current Mediwound Market Capitalisation?

As of today, Mediwound (NASDAQ: MDWD) market cap is 156.210M USD.

What Is Mediwound's (MDWD) Earnings Per Share (TTM)?

The Mediwound EPS is currently -1.63 (Trailing Twelve Months).

When Is the Next Mediwound Earnings Date?

Mediwound's next earnings report will be released on 17/11/2026.

Is MDWD a Buy or Sell From a Technical Analyst Perspective?

Based on today's Mediwound moving averages and other technical indicators, the daily buy/sell signal for MDWD stock is Strong Sell.

How Many Times Has Mediwound Stock Split?

Mediwound has split 1 times. (See the MDWD stock split history page for full effective split date and price information.)

How Many Employees Does Mediwound Have?

Mediwound has 121 employees, based on their latest Companies House report.

What is the current trading status of Mediwound (NASDAQ: MDWD)?

As of 22/10/2026, Mediwound (MDWD) is trading at a share price of 12.100 USD, with a previous close of 12.100 USD. The stock has fluctuated within a day range of 12.010 USD to 12.470 USD, while its 52-week range spans from 11.840 USD to 19.700 USD.

What Is Mediwound (MDWD) Price Target According to Analysts?

The average 12-month price target for Mediwound is 30.667 USD, with a high estimate of 36 USD and a low estimate of 25 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +153.44% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.